Custom bipolar electrode for bleomycin-based electrochemotherapy in patient-derived uveal melanoma in ovo and ex vivo
This study investigated the effects of bleomycin-based ECT delivered using a custom bipolar electrode in UM patient-derived xenografts (PDX).
Introduction: Uveal melanoma (UM) is a rare tumor entity and the predominant primary intraocular malignancy in adulthood. Despite high local tumor control rates, metastatic disease remains frequent and systemic therapeutic options are limited. Electrochemotherapy (ECT) with bleomycin enhances intracellular drug uptake through electroporation (EP), thereby increasing targeted antitumor activity. This study investigated the effects of bleomycin-based ECT delivered using a custom bipolar electrode in UM patient-derived xenografts (PDX).
It demonstrates that a custom bipolar electrode can enhance the therapeutic efficacy of bleomycin-based electrochemotherapy in uveal melanoma, indicating a potential new approach for local control of this aggressive intraocular cancer.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Uveal melanoma as a target for immune-therapy
- Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma
- EORTC and Immunocore Announce Enrolment of First Patient onto the Only Active Phase 3 Adjuvant Trial in Uveal Melanoma
- Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer
- Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma